Nicholas C P Cross

发表

Corrigendum: Exon-centric regulation of ATM expression is population-dependent and amenable to antisense modification by pseudoexon targeting

Igor Vorechovsky, Jana Kralovicova, Marcin Knut, 2016, Scientific Reports.

Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale.

Helen E White, Dong-Wook Kim, Timothy Hughes, 2013, Clinical chemistry.

Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms.

Helen E White, Daniel Ward, Matthew Lyon, 2015, Leukemia research.

The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA.

Nicholas C P Cross, Andreas Hochhaus, Pascual Bolufer, 2002, Human molecular genetics.

Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease.

Philipp Erben, Christoph Walz, Carsten Müller-Tidow, 2011, Blood.

Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome

Andrew Chase, Nicholas C P Cross, A. Chase, 2013, Haematologica.

Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.

Claude Preudhomme, Daniel Birnbaum, Olivier Kosmider, 2012, Blood.

Recurrent SETBP1 mutations in atypical chronic myeloid leukemia

Roberta Spinelli, Rocco Piazza, Torsten Haferlach, 2012, Nature Genetics.

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.

Simona Soverini, Giovanni Martinelli, Thomas Ernst, 2011, Blood.

JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms

Andrew Collins, Andrew Chase, Nicholas C P Cross, 2009, Nature Genetics.

Accurate detection and quantitation of heteroplasmic mitochondrial point mutations by pyrosequencing.

Helen E White, Nicholas C P Cross, A. Seller, 2005, Genetic testing.

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

Peter Marynen, Rafeul Alam, Jan Cools, 2003, The New England journal of medicine.

Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA.

Paul Metcalfe, Helen E White, Susan Branford, 2010, Blood.

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.

Simona Soverini, Giovanni Martinelli, Susan Branford, 2006, Blood.